Parabilis Medicines (PBLS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.36
- Estimate
- -$0.38
- Surprise
- +5.3%
- Revenue (period 2026-09-30)
- $2.1M
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
Parabilis Medicines (PBLS) reported a narrower loss than forecast — adjusted EPS of -$0.36 against the -$0.38 estimate (a 5.3% beat on a still-unprofitable quarter).
Coverage in the report window
- Parabilis Medicines Reports Third Quarter 2026 Financial Results and Business Updates — fiscal.ai, 2026-11-12
- Parabilis Medicines Q3 EPS $(0.36), Inline, Sales $2.114M Beat $375.000K Estimate — benzinga, 2026-11-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates PBLS Sell at 5.6/10; no pre/post engine snapshot brackets this report.
1 of the last 2 quarters beat the estimate; this quarter's +5.3% surprise compares with a -383.8% four-quarter average.
What argues against it
- Quality below floor (3.0 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $27.69
- Price target
- $35.67
- Stop
- $25.75
- Upside to target
- +28.8%
- Reward-to-risk
- 1.9:1
Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.
PBLS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.42B
- P/E (fwd)
- -12.7
- 52-week range
- $22.66–$42.49
- Off 52-week high
- 34.8%
- RSI (14)
- 60
- Volume vs avg
- 0.75×
- Score today
- 5.6/10